
Inventera announced on the 21st that it has confirmed statistically significant improvements across all primary endpoints in the results of its domestic Phase 3 clinical trial for INV-002 (product name NEMO-103 Injection), a novel nano-MRI contrast agent candidate.
According to the final Clinical Study Report (CSR) recently received by Inventera, Magnetic Resonance Arthrography (MRA) using INV-002 demonstrated superiority over non-contrast MRI in all three efficacy indicators presented as primary endpoints: △joint distension, △contrast, and △sharpness.
This Phase 3 trial involved 85 patients requiring MRA due to shoulder joint disorders and was conducted at eight top-tier general hospitals in Korea, including Bundang Seoul National University Hospital. It was a multi-institutional, single-arm study comparing non-contrast MRI images with MRA images using INV-002 from the same patients, with an independent central reader evaluating image quality.
As a result, MRA administered with INV-002 showed clear improvement effects not only in the primary endpoints of joint distension, contrast, and sharpness compared to non-contrast MRI, but also in key image quality indicators such as the Contrast-to-Noise Ratio (CNR) and Lesion-to-Background Ratio (LBR), which were secondary endpoints. Furthermore, it was confirmed that the treatment contributed to improving the reliability of differential diagnosis and diagnosis for major shoulder diseases, including labral tears and articular cartilage tears, which are difficult to detect with non-contrast MRI.
INV-002 is the world's first T1 nano-MRI contrast agent novel drug utilizing biocompatible iron instead of gadolinium, developed targeting MRA for the diagnosis of musculoskeletal diseases. Currently, there are no approved contrast agents for MRA, so INV-002 would become the sole product if approved.
Based on the image quality improvement effects, diagnostic reliability, and administration convenience demonstrated in this clinical trial, Inventera plans to rapidly advance its product approval application and commercialization.
CEO Shin Tae-hyun In Ben-te-ra (CEO) stated, "The excellent image quality improvement effect observed in the interim results was consistently demonstrated in the final CSR as well, proving statistical superiority in all primary endpoints," adding that "successfully completing a Phase 3 clinical trial for an in-house developed novel drug is a significant achievement showcasing Inventera's R&D capabilities."
He continued, "Based on this final report, we plan to file for New Drug Application (NDA) with the Ministry of Food and Drug Safety in the fourth quarter of this year," adding, "We expect substantial revenue generation from INV-002 starting next year after obtaining approval, and will fully accelerate Inventera's growth by leveraging the commercialization of our in-house developed novel drug."